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Enter the era of facilitated anastomotic devices for
coronary bypass surgery
Hani Shennib, MD
During the past 50 years and except for some attempts to usemechanical staplers by the Russian pioneer surgeon Kolosov,almost all proximal and distal aorta-coronary anastomoses havebeen done with conventional hand-held sutures. The comfort tosurgeons in performing a reliable anastomosis with conventionalsuturing has led to its adoption as the gold standard and will likely
be the principal reason for hesitancy in adopting alternate anastomotic methods. So
why change?
Unquestionably, the principal impetus for change in our cardiac surgical practice
has been the desire to offer patients less-invasive therapies, particularly in light of
the rapid growth of percutaneous catheter-based interventional cardiology proce-
dures. Since 1995 and with growing interest in developing platform technology for
minimally invasive coronary artery bypass grafting (CABG), numerous concepts,
devices, techniques, and technologies have been introduced. Some have been
adopted. Others have vanished despite exhaustive efforts by their industrial pro-
moters. (Surgeons may become excited quickly by new devices, but they also have
the intellectual and practical honesty to abandon those that are of no benefit to their
patients.) In fact, in a review of all the instruments developed—including cameras,
scopes, retractors, occluders, and others—stabilizers for coronary artery anastomo-
sis stand alone as the most significant contributors to the growth of beating-heart
CABG. Of all the innovative technology to be considered in the near future,
anastomotic devices, in my opinion, will have the greatest impact on the practice of
CABG.
In general, for any anastomotic device to become widely accepted, it must fulfill
three essential characteristics: facility, precision, and evidence of long-term effec-
tiveness. A device that is cumbersome to set and deploy during surgery will not
likely survive early validation. It must be easy to use.
One of the key advantages of hand-held suturing devices is the ability to tailor
each bite to the exact characteristics of the graft and native vessel. An anastomotic
device must be appropriate for the diseased vessels and for the exact angulation and
layout of the surgical field. Edges must be well coapted with proper sealing and no
impediment to flow. Most important, however, as in all revascularization innova-
tions, the device must provide satisfactory long-term patency. Recent interest in
performing CABG through keyhole incisions has intensified efforts to resolve the
problem of how to perform coronary artery anastomoses through limited access
using endoscopic principles. Endoscopic microsuturing is extremely difficult. Indi-
rect visualization via a camera that replaces direct vision, coupled with the use of
rigid, long instruments, renders the results of endoscopic suturing less than desir-
able. Ironically, very sophisticated and expensive robotic technology has been
suggested to facilitate performance of endoscopic anastomosis, but in a conven-
tional suturing manner,1 rather than through alternative anastomotic concepts. It is
for this reason that robotic technology has failed so far to simplify CABG.
Automated and semiautomated suturing devices are now on the horizon.2 Also
promising is technology that shies away completely from traditional suturing. At
least eight medical technology companies are presently focused on developing
anastomotic devices to replace conventional suturing for proximal and distal
CABGs.
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Challenges confronting this “alternative anastomotic
technology” include success in three areas: delivery, de-
ployment, and durability.
In validating this new technology, surgeons have an
advantage over interventional cardiologists in the ability to
access the chest cavity directly. This will likely expedite the
testing of some anastomotic devices, initially through open
chest methods and without the limitations of complex de-
signs and material made to suit endovascular access. Cath-
eter-based endovascular delivery, which should be the ulti-
mate objective, will necessitate the integration of imaging
technology into the operating rooms and the training of
surgeons on catheter-based techniques. Deployment of new
anastomotic devices in more challenging and complex na-
tive aortas and diseased coronary arteries will likely be the
Achilles’ heel of such devices for some time. Concern with
biocompatibility, thrombosis, and intimal proliferative re-
sponse will necessitate long-term pre-marketing studies for
many of the devices.
In this issue of the Journal, Calafiore and colleagues3
present cutting-edge experience with a new anastomotic
device for performance of proximal CABGs. The principle
of the device is the deployment of a metal connector
mounted within a vascular conduit onto the wall of the
aorta. Like most coronary stents, the device is made of inert
metal with memory. It anchors the graft to the wall of the
aorta by recoiling to its original design. Clinical experience
from other companies with different designs will be forth-
coming. Nitinol stents are only one category of devices that
will soon become available and commonplace in cardiac
surgical practice. Other couplers, molds, and stents based on
different biocompatible material are currently being devel-
oped. Calafiore and associates have shown that it is possible
to implant one such anastomotic device with reasonable
facility and safety. Before stocking our operating room
shelves with it, however, we will need more scientific
validation on the safety, the efficacy, and certainly the
long-term angiographic follow-up of anastomoses created
with this device to confirm its durability.
We also do not yet know whether these anastomotic
devices are practical in aortas with normal wall thicknesses
only or for diseased aortic tissue of varying thicknesses and
densities. Furthermore, is this technique applicable to vein
grafts of average diameter only, or could it be used for
smaller and larger veins? What about arterial grafts? Will
they sustain the shear force of mounting and deploying the
anastomotic device?
So what potential benefits to patients will this technology
offer?
First, this device allows the performance of a quality
anastomosis repeatedly, with consistency, and with minimal
intersurgeon variation. For the first time ever, the coronary
anastomosis will be determined not by the skill of the
surgeon but by the effectiveness of the device. Second, the
device is likely to expedite the procedure and allow several
proximal anastomoses to be done in very little time. Third,
it represents yet another facilitator for performing more
off-pump beating-heart CABGs. Perhaps the most signifi-
cant potential advantage of using this and other forthcoming
proximal aorta-coronary anastomotic devices is the likeli-
hood of less manipulation of the aorta, which will decrease
the risk of aortic embolic showering to the brain and other
organs.
What are the drawbacks?
The only one that I could think of, provided that this
technology will ultimately be applicable to all types and
sizes of vascular grafts, is the high cost. Assuming $330 for
a single application, another $1000 will be added to a triple
bypass operation. This is an untenable price for CABG, a
procedure already limited by other economic restrains.
However, by using this and other facilitating technology, it
may be possible to package a new less-invasive CABG
procedure with reduced operative and postoperative time
and a lower risk of stroke. As more devices are manufac-
tured and used, the price will be reduced.
CABG surgery will never be the same. The drive toward
new less-invasive strategies will assure not only continuous
improvement of surgical outcomes but also an appreciation
of the desire for patients to undergo less onerous operations,
competitive with current percutaneous interventional cardi-
ology procedures. As long-term results of coronary stents
continue to improve, we as surgeons must respond by ad-
vocating new and potentially less-invasive procedures that
offer the only remaining advantage for continuing CABG
today: long-term efficacy.
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